Bladder cancer
First-line therapy of synchronous and metachronous metastatic UCaExtra case 1: Rodrigo (67 years old)
Rodrigo is a 67-year-old, retired video game programmer. He was diagnosed with MIBC (cT3bN0M0) and received 4 cycles of neoadjuvant gemcitabine + cisplatin (GC) + durvalumab followed by RC + PLND without significant complications. Pathological review of the RC specimen indicated ypT2N0 (0/10) R0. He received adjuvant durvalumab for 8 cycles.
First follow-up scans showed no evidence of disease, however, 9 months after completion of durvalumab, he presents with retroperitoneal lymph nodes (up to 3 cm short axes) and multiple lung metastases on CT.
Current situation:
• Medical history: hypertension, chronic kidney disease
• ECOG PS: 1
• GFR: 45 ml/min
• Peripheral neuropathy: grade 1
• Audiometric hearing loss: grade 2
• Biopsy of lung metastasis:
- Pure UCa
- Activating FGFR3 mutation